These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 6345112)

  • 41. A possible mechanism of action of sulfasalazine and 5-aminosalicylic acid in inflammatory bowel diseases: interaction with oxygen free radicals.
    Del Soldato P; Campieri M; Brignola C; Bazzocchi G; Gionchetti P; Lanfranchi GA; Tamba M
    Gastroenterology; 1985 Nov; 89(5):1215-6. PubMed ID: 2864302
    [No Abstract]   [Full Text] [Related]  

  • 42. Cholestyramine-induced inhibition of salicylazosulfapyridine (sulfasalazine) metabolism by rat intestinal microflora.
    Pieniaszek HJ; Bates TR
    J Pharmacol Exp Ther; 1976 Jul; 198(1):240-5. PubMed ID: 6792
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
    Segars LW; Gales BJ
    Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3-year prospective observational study.
    Green JR; Swan CH; Gibson JA; Kerr GD; Swarbrick ET; Thornton PC
    Aliment Pharmacol Ther; 2004 Feb; 19(4):435-42. PubMed ID: 14871283
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sulfasalazine and 5-ASA compounds.
    Allgayer H
    Gastroenterol Clin North Am; 1992 Sep; 21(3):643-58. PubMed ID: 1355468
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.
    Tursi A; Brandimarte G; Giorgetti GM; Forti G; Modeo ME; Gigliobianco A
    Med Sci Monit; 2004 Nov; 10(11):PI126-31. PubMed ID: 15507864
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Determination of the active moiety of BX661A, a new therapeutic agent for ulcerative colitis, by studying its therapeutic effects on ulcerative colitis induced by dextran sulfate sodium in rats.
    Kimura I; Kawasaki M; Nagahama S; Matsuda A; Kataoka M; Kokuba Y
    Arzneimittelforschung; 1998 Nov; 48(11):1091-6. PubMed ID: 9850431
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis.
    Lauritsen K; Hansen J; Ryde M; Rask-Madsen J
    Gastroenterology; 1984 Jun; 86(6):1496-500. PubMed ID: 6143704
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sulfasalazine and 5-aminosalicylic acid inhibit contractile leukotriene formation.
    Nielsen ST; Beninati L; Buonato CB
    Scand J Gastroenterol; 1988 Apr; 23(3):272-6. PubMed ID: 2898806
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Equimolar doses of balsalazide and mesalamine: are we comparing apples and oranges?
    Farrell RJ; Peppercorn MA
    Am J Gastroenterol; 2002 Jun; 97(6):1283-5. PubMed ID: 12094839
    [No Abstract]   [Full Text] [Related]  

  • 51. The effect of the acetylator phenotype on the metabolism of sulphasalazine in man.
    Azad Khan AK; Nurazzaman M; Truelove SC
    J Med Genet; 1983 Feb; 20(1):30-6. PubMed ID: 6133000
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Actions of sulfasalazine and 5-aminosalicylic acid as reactive oxygen scavengers in the suppression of bile acid-induced increases in colonic epithelial cell loss and proliferative activity.
    Craven PA; Pfanstiel J; Saito R; DeRubertis FR
    Gastroenterology; 1987 Jun; 92(6):1998-2008. PubMed ID: 2883067
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of ulcerative colitis with balsalazide: response to editorial by Drs. Farrell and Peppercorn and letter to the editor by Dr. Hanauer.
    Johnson LK; Pruitt RE; Green JR
    Am J Gastroenterol; 2003 Jan; 98(1):216-9. PubMed ID: 12526969
    [No Abstract]   [Full Text] [Related]  

  • 54. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide.
    Lowry PW; Franklin CL; Weaver AL; Szumlanski CL; Mays DC; Loftus EV; Tremaine WJ; Lipsky JJ; Weinshilboum RM; Sandborn WJ
    Gut; 2001 Nov; 49(5):656-64. PubMed ID: 11600468
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [New treatments of hemorrhagic rectocolitis].
    Rambaud JC
    Ann Gastroenterol Hepatol (Paris); 1988; 24(4):173-7. PubMed ID: 2901821
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis.
    d'Albasio G; Trallori G; Ghetti A; Milla M; Nucci A; Pacini F; Morettini A
    Dis Colon Rectum; 1990 May; 33(5):394-7. PubMed ID: 1970284
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis.
    Sutherland LR; May GR; Shaffer EA
    Ann Intern Med; 1993 Apr; 118(7):540-9. PubMed ID: 8095128
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Absorption, enterohepatic circulation, and excretion of 5-aminosalicylic acid in rats.
    Shafii A; Chowdhury JR; Das KM
    Am J Gastroenterol; 1982 May; 77(5):297-9. PubMed ID: 6123257
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis.
    Wiggins JB; Rajapakse R
    Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1279-84. PubMed ID: 19743890
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Salazosulfapyridine or 5-aminosalicylic acid].
    van Hees PA
    Ned Tijdschr Geneeskd; 1987 May; 131(22):931-4. PubMed ID: 2885762
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.